Bronchopulmonary Dysplasia
Conditions
Keywords
Bronchopulmonary Dysplasia, high-flow nasal cannula, noninvasive ventilation, Ventilation mode, premature infant
Brief summary
Bronchopulmonary dysplasia of premature infants is a common respiratory disease in premature infants. Long-term complications such as recurrent respiratory infection and abnormal lung function may occur in the survivors, and may increase the risk of dysplasia of the nervous system. In the past 30 years, although the monitoring and treatment technology of premature infants has been significantly improved, the incidence of BPD still shows no downward trend, and effective treatment and prevention methods for BPD are still lacking. The progress of clinical research on BPD is slow, one of the important reasons is that the definition of BPD is still not consistent, and its diagnostic and grading standards lack objectivity. To summarize the development of diagnostic criteria for BPD in the past 30 years, there are still the following disadvantages. 1. 2. In the above study, all proposed alternative BPD classification standards did not completely separate HFNC and NIV. In view of this, this study separated HFNC(High Flow Nasal Cannula Oxygen) and other NIV(Non-Invasive Ventilation) to form a new revised BPD classification standard. On this basis, a nested case-control study was conducted to compare the differences between the newly proposed classification standards and NICHD(National Institute of Child Health and Human Development) standards in 2001, Rosemary standards in 2018 and Jensen standards in predicting long-term respiratory outcomes and other systemic complications in premature infants, so as to provide a standard for more accurate diagnosis and evaluation of BPD in premature infants.
Interventions
no intervention
Sponsors
Study design
Eligibility
Inclusion criteria
* premature infants whose gestational age is less than 32 weeks; * hospital stay ≥14 days; * complete clinical medical records, including effective follow-up information
Exclusion criteria
* congenital heart and lung malformation and specific chromosomal diseases; * children abandon treatment halfway; * death of children due to factors other than respiratory system.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Respiratory Adverse Outcomes | up to 18 months after birth | Respiratory adverse outcomes include all types of neonatal lung diseases |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Growth Restriction | up to PMA 18-24 months | height, weight or head circumference \<3rd percentile for corrected gestational age and sex, growth percentiles defined using the World Health Organization Child Growth Standards |
| Days of Oxygen Supplement | up to 18 months after birth | days during which the infants were given oxygen supplement |
| Physical Development Outcome | up to 18 months after birth | including length, weight, head circumference |
Countries
China
Contacts
Children's Hospital of Chongqing Medical University
Participant flow
Pre-assignment details
Infants with severe congenital malformations or missing key study data were excluded
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Customized Gestational age | 29.7 weeks STANDARD_DEVIATION 1.4 |
| Birth weight | 1459.5 grams STANDARD_DEVIATION 277 |
| Cesarean section | 73 Participants |
| Prenatal glucocorticosteroids administration | 88 Participants |
| Race/Ethnicity, Customized Chinese Han populations | 270 Participants |
| Sex: Female, Male Female | 58 Participants |
| Sex: Female, Male Male | 84 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 5 / 130 | 14 / 140 |
| other Total, other adverse events | 3 / 130 | 7 / 140 |
| serious Total, serious adverse events | 5 / 130 | 11 / 140 |